AzTrials
AzTrials

Idiopathic GastroparesisPhase 2NCT06899217

A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.

A Phase 2 study testing CIN-102 Dose 15mg and CIN-102 Dose 10mg in people with Idiopathic Gastroparesis, run by CinDome Pharma, Inc. at 85 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help to decrease nausea severity associated with idiopathic gastroparesis severity in adult subjects. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Idiopathic Gastroparesis
What is being tested?
CIN-102 Dose 15mg and CIN-102 Dose 10mg
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
416 participants
Where
85 sitesUnited States
Study dates
29 Jan 2025to 7 May 2026
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Is a male or female ≥18 years of age;
  • Has a current diagnosis of gastroparesis defined by the following:
  • Persistent gastrointestinal (GI) symptoms that, in the opinion of the Investigator, are consistent with gastroparesis within 6 months prior to Screening; and
  • Documented delayed gastric emptying as determined by gastric emptying breath test (GEBT) at Visit 2.
  • Body mass index between 17 and 49 kg/m2, inclusive;
  • If receiving treatment with a Food and Drug Administration (FDA)-approved and marketed glucagon-like peptide-1 receptor agonist (GLP-1RA) for weight loss or reduce risk of major adverse cardiovascular events, and/or, receiving any other agent(s) taken for weight loss, subjects may be considered for the study if ALL of the following criteria are satisfied:
Show all 12Show fewer
  • Is not taking the agent(s) for the management of diabetes or blood glucose;
  • Has been on a stable dose of the agent(s) for at least 3 months before Screening and is expected to maintain the same dose throughout the study, including during GEBT;
  • Is tolerating the agent(s) well, according to the Investigator's judgment;
  • In the opinion of the Investigator, the study-qualifying signs/symptoms of gastroparesis are NOT solely due to the the agent(s); and
  • Symptoms of gastroparesis were present before starting the agent(s).
  • -------------------------------------------------------------------------

Who cannot join

  • Has a known primary cause of gastroparesis (eg, diabetes, surgery; acute, ongoing, or active viral illness; cancer, medications, musculoskeletal or connective tissue disorders [eg, scleroderma, systemic lupus erythematosus], or other neurologic disorder [eg, Parkinson's disease], postural orthostatic tachycardia syndrome (POTS), etc.]);
  • Has a current diagnosis of Type 1 or Type 2 diabetes, according to the American Diabetes Association. Pre-diabetes is not exclusionary;
  • Has been hospitalized for gastroparesis or malnutrition within 3 months prior to Screening;
  • Has a known or suspected GI mechanical obstruction (eg, peptic stricture) as documented by upper GI endoscopy, upper GI radiographic series, plain film abdomen X-ray, or computed tomography (CT) in the past 2 years prior to Randomization;
  • Has a history of pyloric injection of botulinum toxin within 6 months of Screening or planned injection(s) during the study;
  • Has any history of pyloroplasty, pyloromyotomy, or gastric peroral endoscopic myotomy (G-POEM) procedure;
Show all 12Show fewer
  • Has a history of gastric surgery;
  • Has a history of or current diagnosis of intestinal malabsorption, recurrent or chronic pancreatitis, or other pancreatic exocrine disease;
  • Has a history of severe and refractory constipation;
  • Has a history or evidence of clinically significant arrhythmia;
  • Currently receiving parenteral feeding or presence of a nasogastric or other gastric enteral tube (e.g. percutaneous endoscopic gastrostomy [PEG] or percutaneous endoscopic jejunostomy [PEJ] tube) for feeding or decompression; Note: patients receiving enteral feeding via a jejunostomy tube may be included if, in the opinion of the Investigator, the patient is also taking substantial oral solid intake and are not primarily dependent on enteral nutrition
  • Has a substance use disorder or a positive alcohol or positive drug screen.

Trial locations and contacts

85 sites in 1 country.

85 sites in 1 country

United States85 sites

  • Southwest Gastroenterology Associates

    Albuquerque, New Mexico, 87109

  • Summit Clinical Research, LLC

    Athens, Georgia, 30607

  • DelRicht Clinical Research - Atlanta

    Atlanta, Georgia, 30329

  • University of Colorado Anschutz

    Aurora, Colorado, 80045

  • Digestive Health - UT Health Austin

    Austin, Texas, 78712

  • Gastro Health - Birmingham

    Birmingham, Alabama, 35235

  • Treasure Valley Medical Research

    Boise, Idaho, 83706

  • Connecticut Clinical Research Institute, LLC

    Bristol, Connecticut, 06010

  • NY Scientific

    Brooklyn, New York, 11235

  • Hope Clinical Research LLC

    Canoga Park, California, 91303

  • American Family Research Group

    Cape Coral, Florida, 33909

  • Westchester Putnam Gastro

    Carmel, New York, 10512

  • Atrium Health - Center for Gastroenterology and Hepatology MMP

    Charlotte, North Carolina, 28204

  • Capital Digestive Care - Chevy Chase Clinical Research

    Chevy Chase, Maryland, 20815

  • Erick H. Alayo Medical Corporation

    Chula Vista, California, 91910

  • Hometown Urgent Care and Research (Cincinnati)

    Cincinnati, Ohio, 45150

  • Urgent Care Specialists, LLC DBA Hometown Urgent Care and Occupational Health - Columbus

    Columbus, Ohio, 43228

  • Flourish Research - Los Angeles (Covina)

    Covina, California, 91723

  • Zenos Clinical Research

    Dallas, Texas, 75230

  • EPIC Medical Research

    DeSoto, Texas, 75115

  • USA and International Research Inc.

    Doral, Florida, 33126

  • Unique Clinical Trials

    Doral, Florida, 33172

  • Cross Creek Medical Clinic, PA

    Fayetteville, North Carolina, 28304

  • Aa Mrc, Llc

    Flint, Michigan, 48504

  • Gastrointestinal Associates and Endoscopy Center, PA - Flowood

    Flowood, Mississippi, 39232

  • G & L Research, LLC

    Foley, Alabama, 36535

  • Gastro Health - Framingham

    Framingham, Massachusetts, 01702

  • Sanmora Bespoke: Parkway Medical Association

    Glen Burnie, Maryland, 21061

  • Carolina Digestive Diseases & Endoscopy Center

    Greenville, North Carolina, 27834

  • GI Alliance - Gurnee

    Gurnee, Illinois, 60031

  • Susquehanna Research Group, LLC

    Harrisburg, Pennsylvania, 17110

  • Peters Medical Research

    High Point, North Carolina, 27260

  • Galen Medical Group

    Hixson, Tennessee, 37343

  • Advanced Medical Research Group

    Hollywood, Florida, 33021

  • Amir A Hassan, MD, PA

    Houston, Texas, 77089

  • Pioneer Research Solutions Inc.

    Houston, Texas, 77099

  • Hometown Urgent Care and Research - Huber Heights

    Huber Heights, Ohio, 45424

  • Nature Coast Clinical Research

    Inverness, Florida, 34452

  • ENCORE Borland Groover Clinical Research

    Jacksonville, Florida, 32256

  • Rocky Mountain Gastroenterology (RMG)

    Lakewood, Colorado, 80228

  • Gastro Care Institute

    Lancaster, California, 93534

  • Excel Clinical Research

    Las Vegas, Nevada, 89109

  • Digestive Disease Specialists

    Las Vegas, Nevada, 89128

  • Epic Clinical Research

    Lewisville, Texas, 75057

  • Applied Research Center of Arkansas, Inc

    Little Rock, Arkansas, 72205

  • Preferred Research Partners, Inc.

    Little Rock, Arkansas, 72211

  • Downtown L.A. Research Center, Inc.

    Los Angeles, California, 90017

  • University of Louisville

    Louisville, Kentucky, 40202

  • Manassas Clinical Research Center

    Manassas, Virginia, 20110

  • Gastrointestinal Specialists of Georgia PC

    Marietta, Georgia, 30060

  • Tandem Clinical Research

    Marrero, Louisiana, 70072

  • Allied Biomedical Research Institute, Inc.

    Miami, Florida, 33155

  • Advocate Aurora Health Research Institute

    Milwaukee, Wisconsin, 53215

  • Delta Research Partners of West Monroe, LLC

    Monroe, Louisiana, 71201

  • NOLA Research Works

    New Orleans, Louisiana, 70125

  • Advanced Research Institute Inc

    New Port Richey, Florida, 34653

  • Capital Digestive Center

    Norfolk, Virginia, 23502

  • North Hills Medical Research Inc. (North Hills Family Medicine)

    North Richland Hills, Texas, 76180

  • Sensible Healthcare, LLC

    Ocoee, Florida, 34761

  • Advanced Research Institute - Ogden

    Ogden, Utah, 84405

  • Quality Clinical Research, Inc

    Omaha, Nebraska, 68114

  • Temple University Hospital

    Philadelphia, Pennsylvania, 19140

  • Portland Gastroenterology Associates

    Portland, Maine, 04101

  • Advanced Research Institute - Portland

    Portland, Oregon, 97223

  • Advanced Research Institute - Reno

    Reno, Nevada, 89511

  • Bandera Family HealthCare Research, LLC (BFHC)

    San Antonio, Texas, 78249

  • Acclaim Clinical Research

    San Diego, California, 92120

  • GI Alliance - Texas Digestive Disease Consultants - San Marcos

    San Marcos, Texas, 78666

  • Advanced Research Institute - Sandy

    Sandy City, Utah, 84092

  • The Center for Clinical Trials

    Saraland, Alabama, 36571

  • Frontier Clinical Research, LLC - Smithfield

    Smithfield, Pennsylvania, 15478

  • KAD Clinical Research, LLC

    St Louis, Missouri, 63123

  • GCP Research

    St. Petersburg, Florida, 33705

  • PPCP Division of Gastroenterology

    Summerville, South Carolina, 29486

  • Texas Digestive Specialists

    Texas City, Texas, 78550

  • Kansas Medical Clinic, P.A.

    Topeka, Kansas, 66606

  • Del Sol Research Management, LLC

    Tucson, Arizona, 85715

  • Options Health Research

    Tulsa, Oklahoma, 74104

  • Carle Clinic - Urbana Main

    Urbana, Illinois, 61801

  • St. Charles Clinical Research

    Weldon Spring, Missouri, 63304

  • Integrated Clinical Trial Services, Inc

    West Des Moines, Iowa, 50265

  • Focus Clinical Research - West Hills

    West Hills, California, 91307

  • Gastro Intestinal Research Institute of Northern Ohio, LLC

    Westlake, Ohio, 44145

  • Paradigm Research - Wheatridge

    Wheat Ridge, Colorado, 80033

  • Huron Gastroenterology

    Ypsilanti, Michigan, 48197

Other trials in United States

About this study

Official title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.

The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help to decrease nausea severity associated with idiopathic gastroparesis severity in adult subjects.

The main questions it aims to answer are:

Read more
  • To evaluate the efficacy of CIN-102 on symptoms of gastroparesis when given to patients with idiopathic gastroparesis compared to a placebo
  • To evaluate the safety of CIN-102 when given to patients with idiopathic gastroparesis compared to a placebo

Participants will go through the following schedule:

  • Pre-screening (1 visit)
  • Screening \& Lead-In (1-2 visits)
  • Will complete a Gastric Emptying Breath Test (GEBT)
  • Will complete daily diary and other Patient Reported Outcomes (PROs) as described in the protocol to assess eligibility for continued study participation.
  • Lead-In Period (1 visit)
  • 12-week treatment period (7 visits)
  • Study drug taken twice daily by mouth
  • Will complete daily diaries and other PROs as described in protocol
  • 1 week follow-up (1 visit)

Researchers will compare the effects of the following treatments:

  • 15 mg CIN-102, taken orally BID for 12 weeks
  • 10 mg CIN-102, taken orally BID for 12 weeks
  • Placebo for CIN-102, taken orally BID for 12 weeks
Being tested
CIN-102 Dose 15mg, Placebo, CIN-102 Dose 10mg
Keywords
Gastroparesis, Idiopathic Gastroparesis, Vomiting, Early satiety, Bloating, Epigastric pain, Abdominal pain, Delayed gastric emptying, Dopamine receptor antagonist, Nausea, Post-prandial fullness, Stomach pain, Gastric statis, Dysmotility, Gastric motility
Medical subject headings
Gastroparesis, Vomiting, Abdominal Pain, Nausea

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CIN-102 Dose 15mgDrug

    Twice daily for 12 weeks

  • PlaceboDrug

    Twice daily for 12 weeks

  • CIN-102 Dose 10mgDrug

    Twice daily for 12 weeks

Study groups in NCT06899217
Study groupRoleWhat they receive
CIN-102: 15mgExperimental15 mg CIN-102, taken orally BID for 12 weeks
Receives: Drug: CIN-102 Dose 15mg
CIN-102: 10mgExperimental10 mg CIN-102, taken orally BID for 12 weeks
Receives: Drug: CIN-102 Dose 10mg
Placebo for CIN-102Placebo comparatorPlacebo for CIN-102, taken orally BID for 12 weeks
Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The effect of CIN-102 to significantly decrease nausea severity as compared to baseline based on the average ANMS GCSI-DD Nausea Subscale Score.

    The American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary (ANMS GCSI-DD) Nausea Subscale Scores will be averaged into a single value that ranges 0-4 (0 for no symptom and 4 for very severe).

    Measured: Over the last 2 weeks of the 12-week Treatment Period as compared to Baseline

Secondary outcomes (19)

  1. The effect of CIN-102 to significantly decrease the severity of gastroparesis-related symptoms as compared to baseline

    Based on the average ANMS GCSI-DD Total Score, Composite of the Nausea and Vomiting Scores, Vomiting Score, Early Satiety Score, Postprandial Fullness Score, upper Abdominal Pain Score, and Vomiting Severity Score

    Measured: Over the last 2 weeks of the 12-week Treatment Period as compared to Baseline

  2. The percentage of subjects who are identified as responders, defined as archiving an average ≥1 point reduction from baseline on each of ANMS GCSI-DD Nausea Score, Total Score, Composite of Nausea and Vomiting Scores, and individual subscale scores

    • The percentage of subjects achieving an average ≥1 point reduction from baseline, assessed separately for each of the following: ANMS GCSI-DD Nausea Score, Total Score, Composite of the Nausea and Vomiting Scores, and individual subscale scores

    Measured: Over the last 2 weeks of the 12-week Treatment Period as well as over the entire Treatment Period

  3. The percentage of subjects who are identified as responders, defined as archiving an average ≥0.5 point reduction from baseline on each of ANMS GCSI-DD Nausea Score, Total Score, Composite of Nausea and Vomiting Scores, and individual subscale scores

    • The percentage of subjects achieving an average ≥0.5 point reduction from baseline, assessed separately for each of the following: ANMS GCSI-DD Nausea Score, Total Score, Composite of the Nausea and Vomiting Scores, and individual subscale scores

    Measured: Over the last 2 weeks of the 12-week Treatment Period as well as over the entire Treatment Period

  4. The percentage of subjects who are identified as responders, defined as achieving an average ≥30% reduction from baseline for each of following: ANMS GCSI-DD Nausea Score, Total Score, Composite of Nausea and Vomiting Scores, individual subscale scores

    • Occurrence of subjects achieving an average ≥ 30% reduction from baseline, assessed separately for each of the following: ANMS GCSI-DD Nausea Score, Total Score, Composite of the Nausea and Vomiting Scores, and individual subscale scores

    Measured: Over the last 2 weeks of the 12-week Treatment Period as well as over the entire Treatment Period

  5. The percentage of symptom-free days in the ANMS GCSI-DD Nausea Score, Total Score, Composite of the Nausea and Vomiting Scores, individual subscale scores, and vomiting severity scores.

    A symptom-free day is defined as a day with severity of symptoms assessed as "none" [ie, ANMS GCSI-DD scores of 0])

    Measured: Over the 12-week Treatment Period

  6. The percentage of symptomatic weeks for each of the following: ANMS GCSI-DD Nausea Score, Total Score, Composite of Nausea and Vomiting Scores, individual subscale scores, and vomiting severity scores

    A symptomatic week is defined as average ANMS GCSI-DD score ≥ 1

    Measured: Over the 12-week Treatment Period

  7. The percentage of mild, moderate, severe and very severe symptomatic weeks for each of the following: ANMS GCSI-DD Nausea Score, Total Score, Composite of Nausea and Vomiting Scores, individual subscale scores, and vomiting severity scores

    Sponsor to provide definition of each severity score

    Measured: Over the 12-week Treatment Period

  8. The Patient Global Impression of Change (PGIC) value

    • The absolute change in PGIC over the 12-week Treatment Period

    Measured: Over the 12-week Treatment Period

  9. The Patient Global Impression of Severity (PGIS) value

    • The absolute change from baseline to Week 12 in PGIS

    Measured: From baseline to Week 12

  10. The effect of CIN-102 to significantly decrease nausea severity as compared to baseline based on the average ANMS GCSI-DD Nausea Subscale Score.

    The American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary (ANMS GCSI-DD) Nausea Subscale Scores will be averaged into a single value that ranges 0-4 (0 for no symptom and 4 for very severe).

    Measured: Over the final 6 weeks of the 12-week Treatment Period as compared to Baseline

  11. The effect of CIN-102 to significantly decrease the severity of gastroparesis-related symptoms as compared to baseline

    Based on the average ANMS GCSI-DD Total Score, Composite of the Nausea and Vomiting Scores, Vomiting Score, Early Satiety Score, Postprandial Fullness Score, upper Abdominal Pain Score, and vomiting severity scores

    Measured: Over the final 6 weeks of the 12-week Treatment Period as compared to Baseline

  12. The percentage of subjects identified as responders, defined as an average ≥0.5 reduction from baseline on each of ANMS GCSI-DD Nausea Score, Total Score, Composite of Nausea and Vomiting Scores, individual subscale scores, vomiting severity scores

    • Occurrence of subjects with an average ≥ 0.5 reduction from baseline, assessed separately for each of the following: ANMS GCSI-DD Nausea Score, Total Score, Composite of the Nausea and Vomiting Scores, individual subscale scores, and vomiting severity scores

    Measured: Over the last 6 weeks of the 12-week Treatment Period

  13. The percentage of subjects identified as responders, defined as achieving ≥30% reduction from baseline for each: ANMS GCSI-DD Nausea Score, Total Score, Composite of Nausea and Vomiting Scores, individual subscale scores, vomiting severity scores

    • Occurrence of subjects achieving a ≥ 30% reduction from baseline, assessed separately for each of the following: ANMS GCSI-DD Nausea Score, Total Score, Composite of the Nausea and Vomiting Scores, individual subscale scores, and vomiting severity scores

    Measured: Over the final 6 weeks of the 12-week Treatment Period

  14. The percentage of symptom-free days in the ANMS GCSI-DD Nausea Score, Total Score, Composite of the Nausea and Vomiting Scores, individual subscale scores, and vomiting severity scores

    A symptom-free day is defined as a day with severity of symptoms assessed as "none" [ie, ANMS GCSI-DD scores of 0])

    Measured: Over the final 6 weeks of the 12-week Treatment Period

  15. The percentage of symptomatic weeks for each of the following: ANMS GCSI-DD Nausea Score, Total Score, Composite of Nausea and Vomiting Scores, individual subscale scores, and vomiting severity scores

    A symptomatic week is defined as average ANMS GCSI-DD score ≥ 1

    Measured: Over the final 6 weeks of the 12-week Treatment Period

  16. The percentage of moderate, severe and very severe symptomatic weeks for each of the following: ANMS GCSI-DD Nausea Score, Total Score, Composite of Nausea and Vomiting Scores, individual subscale scores, and vomiting severity scores

    Sponsor to provide definition of each severity score

    Measured: Over the final 6 weeks of the 12-week Treatment Period

  17. The Patient Global Impression of Change (PGIC) value

    • The absolute change in PGIC over the 12-week Treatment Period

    Measured: Over the final 6 weeks of the 12-week Treatment Period

  18. The Patient Global Impression of Severity (PGIS) value

    • The absolute change from baseline to Week 12 in PGIS

    Measured: Over the final 6 weeks of the 12-week Treatment Period

  19. To assess the safety of CIN-102 compared to placebo in adult subjects with idiopathic gastroparesis from the time of informed consent until the EOS

    • Incidence of clinically significant changes in laboratory parameters, physical examination findings, 12-lead ECG parameters, weight measurements, and vital signs, as assessed by the Investigator
    • TESAEs
    • TEAEs leading to premature discontinuation of study drug
    • Treatment-emergent clinically significant laboratory abnormalities

    Measured: Over the 12-week Treatment Period

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Mar 2025
  2. Study start29 Jan 2025
  3. Primary completion7 May 2026
  4. Study completion7 May 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
416 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06899217
Sponsor's protocol ID
CIN-102-124
Status last verified
Sep 2025
First submitted
14 Feb 2025
Last updated
13 Jul 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing CIN-102 Dose 15mg and CIN-102 Dose 10mg in people with Idiopathic Gastroparesis, run by CinDome Pharma, Inc. at 85 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 12 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 13 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 85 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The effect of CIN-102 to significantly decrease nausea severity as compared to baseline based on the average ANMS GCSI-DD Nausea Subscale Score. (time frame: Over the last 2 weeks of the 12-week Treatment Period as compared to Baseline). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06899217.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jul 2026; AzTrials last refreshed its copy on 6 Nov 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in